Table 1.

Reported studies evaluating checkpoint inhibitor monotherapy and combination therapy in gynecological cancers

Treatment	Study design	Number	ORR	DCR	Reference
Ovarian
Nivolumab	Phase II	20	15%	45%	Hamanishi et al. [6]
Pembrolizumab	Phase II	376	8% (7 CRs, 23PRs)	37.2%	Matulonis et al. ASCO [8]
Avelumab	Phase Ib	124	9.7%	54%	Disis et al. ASCO [9]
Pembrolizumab + PLD	Phase II	26	19% (5 PRs)	42% (5PR and 6 SD) at 6 mo	Matulonis et al. SGO [23]
Durvalumab + Olaparib	Phase II (BRCA 1/2 WT)	12	17% (2PRs)	83% (2PR and 8 SD)	Lee et al. [28]
BGB-A317 + BGB-290 (PD-1 and PARP)	Phase Ib	38	21% (1CR, 7PR’s)	not reported	Friedlander et al. ASCO [29]
Durvalumab + Olaparib (MEDIOLA)	Phase II (gBRCA 1/2 mutations)	32	63% (6 CRs and 14 PRs)	81% at 12 wks	Drew et al. SGO [30]
Pembrolizumab + Niraparib (TOPACIO)	Phase II (BRCA 1/2 WT and mutants)	36	27% (6 PRs)	50%	Konstantinopoulos et al. SGO [31•]
Mirvetuximab soravtansine + pembrolizumab	Phase Ib	14	43%	not reported	Matulonis et al. SGO [42]
Cervical
Pembrolizumab	Phase Ib/II	71	17%	not reported	Schellens et al. ASCO [65•]
Nivolumab	Phase I/II	24	20.8%	70.8%	Hollebecque et al. ASCO [63]
Ipilimumab	Phase I/II	34	3% (1PR)	32%	Lheureux et al. ASCO [67]
Endometrial
Pembrolizumab	Phase I/II basket (MSI-H)	15	53%	73%	Le et al. [50•]
Pembrolizumab	Phase I basket (MSI-H and MSS)	24	13% (3PRs)	25% (3PRs and 3SD)	Ott et al. ASCO [56•]
Atezolizumab	Phase Ia (MSI-H and MSS)	15	13% (2 PRs)	27%	Fleming et al. ASCO [55]
Avelumab	Phase II (MSI-H and MSS)	31	20% (3PRs) MSI-H only	33% (MSI-H only)	Konstantinopoulos et al. SGO [57]
Pembrolizumab + Lenvantinib	Phase Ib/II (80% MSS)	54	50% (24 weeks)	not reported	Makker et al. ASCO [59•]

PLD pegylated liposomal doxorubicin, ORR overall response rate, DCR disease control rate, PR partial response, SD stable disease, CR complete response, MSI-H microsatellite instability high, MSS microsatellite stable